Literature DB >> 25217005

Adiponectin-resistin index and its strong association with acute coronary syndrome in South Indian men.

Prerna Singh1, M G Sridhar, Medha Rajappa, J Balachander, Tamilarasu Kadhiravan.   

Abstract

BACKGROUND: India has the highest burden of acute coronary syndromes worldwide. Apart from certain lipid alterations that have been established to be definite risk factors, low level of adiponectin, high levels of resistin, and IL-6 have been shown to be risk factors for cardiovascular events. Insulin resistance is also a significant predictor of poor outcome in patients admitted with ACS.
METHODS: 69 male patients with ACS and 70 age-matched healthy males were recruited in the study. Insulin, total adiponectin, resistin, and IL-6 levels were assayed in all study subjects. Indices of insulin resistance and novel adipokine indices were calculated using standard formulae. Multiple logistic regression analysis was done to find out the best predictor of ACS.
RESULTS: Resistin, IL-6, insulin resistance indices, AR index, and IRAR index were found to be significantly higher, while insulin sensitivity indices and total adiponectin were found to be lower in cases, as compared with controls (p < 0.001). Insulin resistance was found to be higher in the admission sample, when compared to the fasting sample in patients with ACS (p = 0.01). On multivariate logistic regression analysis, HOMA-IR and AR index were found to be significantly associated with ACS. AR index was the best independent predictor of ACS, with the highest odds ratio (AR index: adjusted OR 17.528, p < 0.0001 versus HOMA-IR: adjusted OR 1.146, p = 0.001).
CONCLUSIONS: The present results implicate that adipokines are significantly associated with pathogenesis of ACS, warranting adequate and early appropriate treatment to reverse this metabolic dysregulation. In our study, AR index was the best predictor of ACS. Hence, the novel AR index might be useful in routine clinical practice for screening persons with increased risk of future development of ACS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25217005     DOI: 10.1007/s00011-014-0771-z

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  23 in total

1.  Adiponectin and risk of acute coronary syndromes: defining the obesity phenotype.

Authors:  Tobias Pischon; Eric B Rimm
Journal:  Eur Heart J       Date:  2007-01-12       Impact factor: 29.983

2.  Association between plasma adiponectin levels and unstable coronary syndromes.

Authors:  Robert Wolk; Peter Berger; Ryan J Lennon; Emmanouil S Brilakis; Diane E Davison; Virend K Somers
Journal:  Eur Heart J       Date:  2006-11-07       Impact factor: 29.983

Review 3.  Burden of coronary heart disease in India.

Authors:  Rajeev Gupta
Journal:  Indian Heart J       Date:  2005 Nov-Dec

4.  Plasma resistin associated with myocardium injury in patients with acute coronary syndrome.

Authors:  Songyun Chu; Wenhui Ding; Kang Li; Yongzheng Pang; Chaoshu Tang
Journal:  Circ J       Date:  2008-08       Impact factor: 2.993

5.  [Association of resistin gene 3'UTR+62G>A polymorphism with insulin resistance, adiposity and the adiponectin-resistin index in Mexican population].

Authors:  Efraín Chavarria-Ávila; Sandra Luz Ruíz Quezada; Milton-Omar Guzmán-Ornelas; Jorge Castro-Albarrán; Maria Elena Aguilar Aldrete; Mónica Vásquez-Del Mercado; Rosa-Elena Navarro-Hernández
Journal:  Nutr Hosp       Date:  2013-11-01       Impact factor: 1.057

6.  Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices.

Authors:  Krzysztof C Lewandowski; Konrad Szosland; Chris O'Callaghan; Bee K Tan; Harpal S Randeva; Andrzej Lewinski
Journal:  Mol Genet Metab       Date:  2005-02-12       Impact factor: 4.797

7.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.

Authors:  T Killip; J T Kimball
Journal:  Am J Cardiol       Date:  1967-10       Impact factor: 2.778

8.  Implications of plasma concentrations of adiponectin in patients with coronary artery disease.

Authors:  Y Nakamura; K Shimada; D Fukuda; Y Shimada; S Ehara; M Hirose; T Kataoka; K Kamimori; S Shimodozono; Y Kobayashi; M Yoshiyama; K Takeuchi; J Yoshikawa
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

9.  Relationship between resistin level in serum and acute coronary syndrome or stable angina pectoris.

Authors:  Xiao-zhi Qiao; Yun-mei Yang; Zhe-rong Xu; Li-ai Yang
Journal:  J Zhejiang Univ Sci B       Date:  2007-12       Impact factor: 3.066

10.  Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up.

Authors:  Radoslaw Kreçki; Maria Krzemińska-Pakuła; Jan Z Peruga; Piotr Szcześniak; Piotr Lipiec; Karina Wierzbowska-Drabik; Daria Orszulak-Michalak; Jarosław Damian Kasprzak
Journal:  Med Sci Monit       Date:  2011-01
View more
  3 in total

Review 1.  The Role of Adipocytokines in Coronary Atherosclerosis.

Authors:  Luca Liberale; Aldo Bonaventura; Alessandra Vecchiè; Matteo Casula; Franco Dallegri; Fabrizio Montecucco; Federico Carbone
Journal:  Curr Atheroscler Rep       Date:  2017-02       Impact factor: 5.113

Review 2.  Perivascular adipose tissue (PVAT) in atherosclerosis: a double-edged sword.

Authors:  Xiao-Yan Qi; Shun-Lin Qu; Wen-Hao Xiong; Oren Rom; Lin Chang; Zhi-Sheng Jiang
Journal:  Cardiovasc Diabetol       Date:  2018-10-10       Impact factor: 9.951

3.  Triglyceride Glucose-Body Mass Index Is a Simple and Clinically Useful Surrogate Marker for Insulin Resistance in Nondiabetic Individuals.

Authors:  Leay-Kiaw Er; Semon Wu; Hsin-Hua Chou; Lung-An Hsu; Ming-Sheng Teng; Yu-Chen Sun; Yu-Lin Ko
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.